Earnings Call Summary | Relmada Therapeutics(RLMD.US) Q2 2024 Earnings Conference
Earnings Call Summary | Relmada Therapeutics(RLMD.US) Q2 2024 Earnings Conference
The following is a summary of the Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript:
以下是Relmada Therapeutics,Inc.(RLMD) Q2 2024 业绩会议录摘要:
Financial Performance:
金融业绩:
Relmada reported a decrease in R&D expenses for Q2 2024 to $10.7 million from $13.7 million in Q2 2023, attributing the decline to the completion of studies.
General and administrative expenses also decreased to $8.1 million in Q2 2024 from $12.3 million in the same period last year, mainly due to reduced stock-based compensation.
The net loss for the quarter was $17.8 million, compared to $25.3 million in Q2 2023.
Cash, cash equivalents, and short-term investments as of June 30, 2024, stood at approximately $70.4 million compared to $96.3 million as of December 31, 2023.
Relmada报告Q2 2024年的研发费用下降至1070万美元,而Q2 2023年为1370万美元,将这一下降归因于研究完成。
总和行政费用也从去年同期的1230万美元下降至Q2 2024的810万美元,主要是由于股票授予减少。
本季度净亏损为1780万美元,而Q2 2023年为2530万美元。
截至2024年6月30日,现金、现金等价物和短期投资约为7040万美元,而截至2023年12月31日为9630万美元。
Business Progress:
业务进展:
Relmada is moving forward with its Phase 3 studies for REL-1017, targeting major depressive disorders, and plans to complete enrollment soon.
Announced plans to initiate a Phase 1 study for REL-P11, a psilocybin program intended for metabolic diseases, with Phase 2a to start in H1 2025.
Relmada正在推进针对重度抑郁症的REL-1017第3期研究,并计划很快完成招募。
宣布计划启动REL-P11的第1期研究,这是一项针对代谢疾病的赛洛西宾计划,第2a期将于2025年上半年开始。
Opportunities:
机会:
Planned completion of Phase 3 studies for REL-1017 could potentially lead to NDA submission, opening avenue to new markets if approved.
Launching a Phase 1 study for REL-P11 highlights expansion into treatment for metabolic disorders.
REL-1017第3期研究计划的完成可能会导致新药申请提交,如果获得批准,将开辟新市场。
启动REL-P11第1期研究突显了公司扩展治疗代谢性疾病的进展。
Risks:
风险:
The company acknowledged an approximately 80% screen failure rate in current studies versus 50% in prior studies, indicating potentially stringent or misaligned enrollment criteria that could delay timelines or affect study outcomes.
公司承认当前研究的筛选失败率约为80%,而先前的研究为50%,表明可能存在严格或不合适的招募标准,这可能会延迟时间表或影响研究结果。
More details: Relmada Therapeutics IR
更多详情:Relmada Therapeutics IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由AI生成。文章内容的准确性无法完全保证。有关更全面的详细信息,请参阅IR网站。本文只是为投资者提供参考,没有任何指导或推荐建议。